Demographic and clinical characteristics of evaluable study population (n=16)
| Characteristic | N | % |
| Age at consent | ||
| N | 16 | |
| Mean (SD) | 54.44 (9.95) | |
| Median (min-max) | 57.50 (33.00–70.00) | |
| # of Prior Tx | ||
| N | 16 | |
| Mean (SD) | 2.63 (1.78) | |
| Median (min-max) | 2.00 (1.00–8.00) | |
| # of cells | ||
| N | 16 | |
| Mean (SD) | 1.30e+11 (2.07e+11) | |
| Median (min-max) | 7.60e+10 (2.03e+10–1.5e+11) | |
| # of IL-2 doses | ||
| N | 16 | |
| Mean (SD) | 5.00 (1.71) | |
| Median (min-max) | 6.00 (1.00–6.00) | |
| Race | ||
| Asian | 1 | 6.25 |
| White or Caucasian | 15 | 93.75 |
| Gender | ||
| Female | 8 | 50.00 |
| Male | 8 | 50.00 |
| Ethnicity | ||
| Hispanic or Latino | 1 | 6.25 |
| Not Hispanic or Latino | 15 | 93.75 |
| Cohort | ||
| Colorectal | 8 | 50.00 |
| Ovarian | 3 | 18.75 |
| Pancreatic | 5 | 31.25 |
| Prior ICI Tx | ||
| No | 14 | 87.50 |
| Yes | 2 | 12.50 |
| Best overall response | ||
| PD | 6 | 37.50 |
| SD | 10 | 62.50 |
| Colorectal | ||
| PD | 3 | 37.50 |
| SD | 5 | 62.50 |
| Ovarian | ||
| PD | 1 | 33.33 |
| SD | 2 | 66.67 |
| Pancreatic | ||
| PD | 2 | 40.00 |
| SD | 3 | 60.00 |
PD, progressive disease; SD, stable disease.